摘要
目的分析2017—2021年杭州市人乳头瘤病毒(HPV)疫苗疑似预防接种异常反应(AEFI)发生情况,为HPV疫苗安全性监测与评价提供依据。方法通过中国疾病预防控制信息系统AEFI监测模块收集2017—2021年杭州市报告的二价HPV疫苗(HPV2)、四价HPV疫苗(HP4)和九价HPV疫苗(HPV9)AEFI资料,通过浙江省疫苗和预防接种综合管理信息系统收集HPV疫苗接种资料,分析AEFI发生情况、发生时间分布和临床症状等。结果2017—2021年杭州市累计接种HPV疫苗922310剂,报告AEFI 232例,报告发生率为25.15/10万剂,其中HPV2、HPV4、HPV9报告发生率分别为31.13/10万剂、25.93/10万剂和22.01/10万剂。以一般反应和异常反应为主,报告发生率分别为21.58/10万剂和2.60/10万剂。接种后0~1 d AEFI发生比例较高,165例占71.12%。主要临床症状为注射部位局部红肿、硬结和发热,报告发生率分别为10.30/10万剂、5.96/10万剂和6.18/10万剂。结论2017—2021年杭州市HPV疫苗AEFI报告发生率较低,临床症状较轻,各类HPV疫苗安全性良好。
Objective To investigate the incidence of adverse events following immunization(AEFI)of human papillomavirus(HPV)vaccines in Hangzhou City from 2017 to 2021,so as to provide insights into safety monitoring and evaluation for HPV vaccines.Methods The AEFI caused by immunization of bivalent(HPV2),quadrivalent(HPV4)and nonavalent HPV vaccines(HPV9)reported in Hangzhou City from 2017 to 2021 were captured from the AEFI Surveillance Module of Chinese Disease Control and Prevention Information System,and HPV vaccination data were captured from the Zhejiang Municipal Immunization Information Management System.The incidence,temporal distributions and clinical symptoms of AEFI were analyzed.Results Totally 922310 doses of HPV vaccines were immunized in Hangzhou City from 2017 to 2021,and 232 cases with AEFI were reported,with an overall incidence rate of 25.15/10~5 doses.The reported incidence rates of AEFI caused by HPV2,HPV4 and HPV9 vaccination were 31.13/10~5doses,25.93/10~5doses and 22.01/10~5 doses,respectively.General reactions and abnormal reactions were predominant AEFI,and the reported incidence rates of general reactions and abnormal reactions were 21.58/10~5 doses and 2.60/10~5 dose,respectively.AEFI predominantly occurred 0 to 1 day post-immunization(165 cases,71.12%),and the main clinical symptoms included local swelling of injection sites,hard tubercle and fever,with reported incidence rates of 10.30/10~5 doses,5.96/10~5 doses and 6.18/10~5 doses,respectively.Conclusions Low incidence of AEFI was reported following HPV vaccination in Hangzhou City from 2017 to 2021,and all AEFI were mild.The safety of HPV2,HPV4 and HPV9 remains high.
作者
江伟
刘艳
杜渐
许玉洋
车鑫仁
王婧
王骏
张学潮
顾雯雯
张小平
JIANG Wei;LIU Yan;DU Jian;XU Yuyang;CHE Xinren;WANG Jing;WANG Jun;ZHANG Xuechao;GU Wenwen;ZHANG Xiaoping(Department of Immunization Program,Hangzhou Center for Disease Control and Prevention,Hangzhou,Zhejiang 310021,China)
出处
《预防医学》
2023年第1期71-73,77,共4页
CHINA PREVENTIVE MEDICINE JOURNAL
基金
杭州市医药卫生科技项目(A20210314)。
关键词
人乳头瘤病毒疫苗
疑似预防接种异常反应
监测
疫苗安全性
human papillomavirus vaccine
adverse event following immunization
surveillance
vaccine safety
